

APR - 5 2004

K040164
Page 1 of 2

510(k) SUMMARY

Submitter Personal Products Company Division of McNeil-PPC Inc.
199 Grandview Road
Skillman, New Jersey 08558-9418

Contact Person Marylou P. Carlson
Mgr. Regulatory Affairs
(908) 904-3709 phone
(908) 904-3748 fax

Date Prepared January 23, 2004

Proprietary Name K-Y® Brand
WARMING Jelly Personal Lubricant

Common Name Personal Lubricant

Classification Name Condom: 21CFR § 884.5300 Product Code 85HIS
Patient Lubricant: 21CFR 880.6375 Product Code MMS

Predicate Device K-Y® Brand Warming LIQUID Personal Lubricant
K-Y® Brand JELLY Personal Lubricant

Description of Device

K-Y® Brand WARMING Jelly is a non-sterile, clear, non-staining, non-greasy, water soluble jelly for use as a personal lubricant. This product imparts a gentle warming sensation when applied to the genitalia. This product was designed to meet a customer need for a lubricant that does not feel cold when applied. K-Y® Brand Warming Jelly reduce can reduce friction during sexual intercourse thereby enhancing sexual intimacy. It is compatible with latex condoms as demonstrated in Condom Compatibility Testing conducted according the standards as defined by ASTM D 3492. K-Y® Brand WARMING Jelly is not a contraceptive nor spermicide.

Intended Use

K-Y® Brand WARMING Jelly is intended as personal lubricant to be used with or without a condom. The lubricous nature of this product helps to supplement the body's own natural lubricating fluids, thereby relieving friction to help enhance the ease and comfort of intimate sexual activity. This lubricant may be safely applied to vaginal, anal or penile tissues for purpose of lubrication, and moisturization and is compatible with latex condoms. K-Y® Brand WARMING Jelly has the additional benefit of imparting a warming sensation when applied to the genital area.

Regulatory Status

Per 21CFR, 880.6375, Patient lubricant is defined as Class I medical device intended for medical purposes that is used to lubricate a body orifice to facilitate entry of a diagnostic or therapeutic device. When used as an accessory to a condom, (a Class II medical device) the lubricant is reviewed by FDA as a Class II Medical Device requiring 510(k) clearance.

00-000201

510(k) SUMMARY (continued)

Technological Characteristics

The K-Y® Brand WARMING Jelly Personal Lubricant formula is proprietary. The product, has no exceptional technological characteristics and consists mainly of safe water-soluble ingredients somewhat similar to other K-Y® Brand personal lubricants currently on the market.

Substantial Equivalence

K-Y® Brand WARMING Jelly Personal Lubricant has been shown, in laboratory tests, to be substantially equivalent to the currently marketed K-Y® Brand Warming LIQUID Personal Lubricant. Both devices have the same intended use with a variation in formula ingredients. The gentle warming technology is the unique feature of the K-Y® Brand WARMING lubricant products.

Preclinical Testing of Formulation

Biocompatibility studies according to International Standard ISO 10993 and General Program Memorandum G95-1 on K-Y® Brand WARMING Jelly were conducted by an outside laboratory, in compliance with Good Laboratory Practices (GLPs). Results from these studies, demonstrated that K-Y® Brand WARMING Jelly was not considered to be a contact sensitizing agent, nor was it associated with systemic toxicity.

Human Clinical Testing

In a Human Repeated Insult Patch Test (Modified Draize Procedure), this product was compared to the currently marketed K-Y® Warming LIQUID for its potential for contact sensitization. Under the conditions of this test no evidence of contact sensitization was elicited.

A Consumer Perception Study evaluated both male and female participant's experience of warmth with a single application of the product to their genitals during an on-site visit. Overall 75.50% of the participants rated the product as Excellent, Very Good or Good for "*Warms on Contact*". There were no adverse events observed or reported during the course of this study.

An In Home Consumer Use Study was conducted to evaluate both consumer perception of warmth during sexual activity as well as the tolerability of the product through vulvo/vaginal speculum examination prior and post product use. Consented female subjects received gynecological examinations at baseline and following the last coital episode. The study was conducted in compliance with 21CFR Part 812 for Investigational Device Exemption and 21CFR Parts 50 and 56. Efficacy results for this study concluded that in 245 reported responses, 91.67% were positive for "*Warms on Contact*" and 85.01% were positive for "*Enhances Intimacy*" and 8.6% responded positively to "*experienced discomfort*". Additionally, after two weeks of home use, (with a minimal of two sexual intercourse encounters) there were no serious adverse events reported. Gynecological examinations detected only one instance of mottled irregular erythema of the inner thigh area at baseline, which was not present at the return visit. It was concluded that the product did not cause irritation as determined by final gynecological examination.

Preclinical and Clinical testing have provided scientific evidence that this product is safe for its intended use.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

FEB 24 2014

Ms. Marylou (Panico) Carlson
Manager, Regulatory Affairs
Personal Products Company
Division of McNeil-PPC, Inc.
199 Grandview Road
SKILLMAN NJ 08558

Re: K040164
Trade/Device Name: K-Y® Brand Warming Jelly
Regulation Number: 21 CFR §884.5300
Regulation Name: Condom
Regulatory Class: II
Product Code: NUC
Dated (Date on orig SE ltr): January 23, 2004
Received (Date on orig SE ltr): January 26, 2004

Dear Ms. Carlson:

This letter corrects our substantially equivalent letter of April 5, 2004.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be

found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Benjamin R. Fisher -S

Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K040164

Device Name: K-Y® Brand Warming Jelly

Indications For Use: **Personal Lubricant**
For vaginal/penile and condom application during
sexual intimacy


Prescription Use _____
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use X _____
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)


(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K040164